EMEA-001810-PIP01-15
Key facts
| Active substance |
L-Cysteine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-α -aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0259/2015
|
| PIP number |
EMEA-001810-PIP01-15
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
Treatment of high-grade glioma
|
| Route(s) of administration |
Intradermal use
|
| Contact for public enquiries |
Celldex Therapeutics, Inc.
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|